Testing the hypothesis: a focused pilot for AI in healthcare

Every scientific breakthrough begins with a question: can this medicine extend life, restore balance, or meaningfully change what is possible for patients? At Ipsen, we are bringing that same discipline to artificial intelligence, asking whether it can help our teams analyse data in new ways, reduce rework and make better, faster decisions in pursuit of science with purpose.

This is the aim of our pilot with the Claude for healthcare and life science team: to test hypotheses in real research and business workflows, measure impact and learn quickly with responsibility embedded from the outset.

Launched in May 2026, the pilot brings together over 40 colleagues across Ipsen’s Research & Development and Medical organizations to work on a defined set of use cases spanning external innovation assessments, scientific literature synthesis, knowledge generation and clinical development workflows. The objective is to focus on high-value activities where teams routinely navigate large amounts of complex data and must produce consistent, high-quality outputs. Participants are exploring the platform using tools including Claude Science and Claude Code.

In healthcare, how AI is used matters as much as what it can do. This pilot is therefore being run with a strong focus on governance, appropriate access, ensuring the right controls are in place and that teams use these tools responsibly.

This is not AI for AI’s sake. Ipsen’s ambition is to bring medicines to patients sooner. This pilot is a focused test of where AI can support that ambition, responsibly and with scientific rigour. Not every step in the delivery of medicines to patients can be accelerated but improving how and when decisions are made and reducing friction in complex analytical work, can make a meaningful difference.

https://www.ipsen.com/stories/science/testing-the-hypothesis-a-focused-pilot-for-ai-in-healthcare